X4 Pharmaceuticals Inc XFOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
Trading Information
- Previous Close Price
- $3.17
- Day Range
- $2.98–3.20
- 52-Week Range
- $2.43–4.83
- Bid/Ask
- $2.95 / $3.14
- Shares Outstanding
- 102.11M
- Market Cap
- $318.59M
- Volume/Avg
- 501,341 / 854,980
Key Statistics
- Price/Earnings (Normalized)
- 5.09
- Price/Sales
- 22.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 45
- Website
- https://www.x4pharma.com
Valuation
Metric | XFOR |
|---|---|
Price/Earnings (Normalized) | 5.09 |
Price/Book Value | 2.27 |
Price/Sales | 22.55 |
Price/Cash Flow | — |
Price/Earnings
XFOR
Financial Strength
Metric | XFOR |
|---|---|
Quick Ratio | 12.62 |
Current Ratio | 13.22 |
Interest Coverage | −9.19 |
Quick Ratio
XFOR
Profitability
Metric | XFOR |
|---|---|
Return on Assets (Normalized) | −30.11% |
Return on Equity (Normalized) | −51.23% |
Return on Invested Capital (Normalized) | −32.92% |
Return on Assets
XFOR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$xV#vs | LOCK|!MdL | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|h^vD?@ | LOCK|nl<z | $99B | |||
| Moderna Inc MRNA | LOCK|&!GmKxj | LOCK|<r | $90B | |||
| argenx SE ADR ARGX | LOCK|>yNz<!! | LOCK|Gz | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|lb&jBj? | LOCK|^^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&Q^VgSsT | LOCK|Ly@X | $31B | |||
| Incyte Corp INCY | LOCK|!cSg&< | LOCK|TL> | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%PH?$&> | LOCK|j>Dz | $22B | |||
| BioNTech SE ADR BNTX | LOCK|xN^JWS | LOCK|LdT | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|q%wD>y | LOCK|CB | $16B |
United States